Physician profile
Thomas Cocke
NPI 1972508554
$3,306.07
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $2,290 · 2021: $203 · 2022: $49.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,485.33 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $178.30 | 2019-2021 | |
| Edwards Lifesciences Corporation | $160.11 | 2021 | |
| Abiomed | $143.04 | 2019-2020 | |
| Abbott Laboratories | $138.78 | 2020-2022 | |
| Boston Scientific Corporation | $104.52 | 2019 | |
| Pfizer INC. | $30.70 | 2019-2020 | |
| Amgen INC. | $27.75 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.73 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.02 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cocke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.